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Abstract
Background: Non-invasive surrogate measures which are valid and responsive to change are
needed to study cardiovascular risks in HIV. We compared the construct validity of two
noninvasive arterial measures: carotid intima medial thickness (IMT), which measures anatomic
disease; and brachial flow-mediated vasodilation (FMD), a measure of endothelial dysfunction.
Methods: A sample of 257 subjects aged 35 years or older, attending clinics in five Canadian centres,
were prospectively recruited into a study of cardiovascular risk among HIV subjects. The relationship
between baseline IMT or FMD and traditional vascular risk factors was studied using regression analysis.
We analyzed the relationship between progression of IMT or FMD and risk factors using fixed-effects
models. We adjusted for use of statin medication and CD4 count in both models.
Results: BaselineIMTwassignificantlyassociatedwithage(p<0.001),malegender(p=0.034),current
smoking status (p < 0.001), systolic blood pressure (p < 0.001) and total:HDL cholesterol ratio
(p = 0.004), but not statin use (p = 0.904) and CD4 count (p = 0.929). IMT progression was significantly
associatedwithage(p<0.001),malegender(p=0.0051)andcurrentsmokingstatus(p=0.011),butnot
statin use (p = 0.289) and CD4 count (p = 0.927). FMD progression was significantly associated with
currentstatinuse(p=0.019),butnotCD4count(p=0.84).NeitherextentnorprogressionofFMDwas
significantly associated with any of the examined vascular risk factors.
Conclusion: IMT correlates better than FMD with established cardiovascular risk factors in this
cohort of HIV patients. Standardization of protocols for FMD and IMT will facilitate the comparison
of results across studies.
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HIV patients may have a higher risk of developing
cardiovascular diseases than the general population
[1-3]. This higher risk may be attributed to HIV infection
or to individual drugs (or drug classes) used in treating
the infection [1,4]. In particular, studies have shown that
protease inhibitors [4] and nucleoside reverse transcrip-
tase inhibitors such as abacavir and didanosine are
associated with increased risk of myocardial infarction in
HIV patients [5].
Cardiovascular disease is often characterized by devel-
opment of atherosclerosis, in which plaque is accumu-
lated on the inside of arterial walls [6]. The reference
standard for assessing extent of atherosclerosis is
coronary angiography, which is costly, invasive and has
occasional complications such as vascular injury [7].
Inexpensive, reproducible, validated, non-invasive mea-
surement of sub-clinical atherosclerosis involves the use
of ultrasound (US) methods for imaging the carotid and
branchial arteries [8-10]. Summary measures obtained
from arterial wall thickness have been used as surrogates
of extent, severity and progression of atherosclerosis in
numerous studies of cardiovascular health involving
diverse patient populations [10]. Examples of such
measures include carotid intimal medial thickness
(IMT), brachial artery flow-mediated vasodilation
(FMD) and plaque area [10,11].
Carotid IMT is a measure of anatomic disease, used to
identify and determine the extent of early arterial wall
changes or structural vascular abnormalities [10,12-14].
Increased carotid IMT is a strong predictor of acute
coronary events [10,14,15], and is significantly asso-
ciated with established cardiovascular risk factors among
various study populations [1,9,10,13,14,16-18].
Brachial FMD is a non-invasive and validated measure of
endothelial function [19,20]. The endothelium helps to
maintain vascular health by releasing both paracrine and
autocrine factorssuchasnitricoxide(alsocalledendothelium-
derived relaxing factor). Nitric oxide (NO) promotes smooth
muscle relaxation, inhibition of platelet aggregation and
adhesion, vasodilation and increased blood flow [21,22].
Thus, endothelial generation of NO is protective against
atherogenesis[22]. A reduction inendothelial release of NO
indicatesendothelialdysfunctionandisregardedasanearly
evidence of atherosclerosis [21-25]. Individuals with cor-
onary artery disease (CAD) may exhibit impaired brachial
FMD responses in the brachial arteries [11,20,26].
Impaired brachial FMD has been shown to be signifi-
cantly associated with cardiovascular risk factors in some
[11,24,27], but not all, studies [13,28]. Also, there are
conflicting results regarding the association between
brachial FMD and cardiovascular events in various
patient populations [20,29].
Non-invasive surrogate measures which are valid and
responsive to change are needed to study cardiovascular
risks associated with HIV or HIV treatment regimens.
There are limited data on the relationship between
extent/progression of carotid IMT or brachial FMD and
traditional vascular risk factors in HIV patients. Further,
the relationship between carotid IMT and brachial FMD
has not been well studied in HIV patients. In this study,
we compare the validity and responsiveness to change of
two ultrasound measures: 12-segment carotid artery IMT
and brachial artery FMD in Canadian HIV vascular study
participants. We also investigate the relationship
between these two measures.
Methods
Study design and study population
HIV patients aged 35 years or older, attending university-
affiliated clinics in five Canadian centers (Hamilton,
Toronto, Calgary, Quebec City and Vancouver) are being
recruited into an ongoing five-year, prospective, multi-
center cohort study to evaluate the association between
atherosclerotic progression, anti-retroviral drug regimen,
immune reconstitution and standard cardiovascular risk
factors. Subjects are recruited regardless of cardiovascular
risk factors or past cardiac history. The study was
approved by research ethics boards of each study site,
and informed consent was obtained from all participants.
All participants provide a medical history and undergo
yearly high-resolution ultrasound using a standardized
protocol and centralized reading. As of March 2008, 257
subjects had baseline measurements for carotid IMT and
brachial FMD, with 168 patients having one-year follow-
up assessments. Measurement of carotid IMT is ongoing,
butbrachialFMDwasdiscontinuedafterone-yearfollow-
upduetocostconsiderations.Forthisancillarystudy,two
datasets were created namely: (1) cross-sectional data
consisting of 257 patients with baseline carotid IMT and
brachial FMD; and (2) progression data consisting of 168
patients with baseline and follow-up measurements for
c a r o t i dI M Ta n db r a c h i a lF M D( F i g u r e1 ) .
Clinical characteristics
Data on demographic and certain clinical characteristics
of subjects were collected at each centre using ques-
tionnaires administered by research staff, or by chart
review. Blood pressure was measured twice using a
mercury sphygmomanometer, and results averaged.
Lipids (total and HDL cholesterol and triglycerides)
were measured after overnight fast. LDL-cholesterol
concentration was calculated by the Friedewald formula.
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analysis performed by the Hamilton Regional Laboratory
Medicine Program, and plasma HIV viral load were
measured by Chiron bDNA assay at the Central Public
Health Laboratory in Toronto, Ontario.
Ultrasound methods
Ultrasound imaging and readings are conducted by trained
personnel using high resolution B-mode ultrasonography,
standardized protocol and centralized reading. The ultra-
sound laboratory in each study site uses imaging systems
equipped with 7.5 to 10 MHz linear phase-arrayed vascular
transducers. The same imaging system is used for all
ultrasound imaging within each center. Ultrasound mea-
surements are recorded on S-VHS tapes, which are later
digitized and analyzed offline at the Core Carotid Ultra-
sound Laboratory (Hamilton, Ontario) by a certified reader
blinded to patients' clinical information.
Patients were advised to fast and abstain from caffeine/
vasoactivemedications12hourspriortomeasurement,and
were advised to avoid cigarette smoking (second-hand
inclusive) at least four hours prior to imaging. Imaging for
carotidIMTwasdonebeforebrachialFMDonthesameday.
(A) 12-segment carotid intimal medial thickness (IMT)
Carotid IMT identifies and quantitates early arterial wall
changes or structural vascular abnormalities [10,12,13]. A
rigorously-standardized, reliable, validated method of '12-
segment carotid IMT' developed by Lonn et al [8,30] was
usedtoassesstheglobalextentofatherosclerosisinpatients.
Imagesofsixwell-definedsegments(nearandfarwallofthe
common carotid, the bifurcation and the internal carotid)
were obtained in each of the left and right carotid arteries
using high resolution B-mode ultrasonography.
Ultrasound measurements were recorded on S-VHS
tapes, which were later digitized and analyzed using
the Image-Pro V4.5.1 software (Glen Burnie, Maryland).
For each segment a minimum of three frames were
measured. The maximum of all measurements from each
segment were summed-up and divided by 12 to obtain
the "12-segment mean-maximal carotid IMT" [8].
Twelve-segment mean-maximal carotid IMT is higher in
individuals with CAD [8,30].
(B) Brachial flow-mediated vasodilation (FMD)
Brachial FMD was measured using an extensively
validated and reliable method [13,31-33]. End-diastolic
ultrasound images of the brachial artery diameter
(longitudinally and slightly above the antebrachial fossa
or upper arm) were obtained at rest and during
vasodilator response induced by passive hyperemia
(endothelium-dependent dilation).
Each patient rested in a quiet room for 10 minutes, after
which sequential images of the brachial artery were
obtained within a 45 second interval. Subsequently, a
blood pressure cuff was inflated around the right lower arm
to at least 200 mm Hg, resulting in occlusion of blood flow
to the upper arm. The cuff was released after five minutes,
resulting in a marked increase in blood flow due to
resistance vessel dilation. The increase in blood flow
stimulates the release of NO which mediates the dilation
of conduit vessels. Peak brachial artery dilation occurs
approximately one minute after cuff release [26]. Another
set of sequential images was obtained during peak dilation.
The ultrasound image frames obtained were recorded on
S-VHS tapes, from which brachial artery diameters were
calculated using Dynamic Endothelial Assessment (DEA)
software (Montreal, Quebec). Average diameter of
brachial artery (before and after dilation) was obtained
from nine sequential images taken at rest and 12 taken
during peak artery dilation. Percent flow mediated
dilation was expressed as
FMD%
average diameter at peak dilation  average diameter a
=
− t t rest
average diameter at rest
() ⎡
⎣
⎢
⎤
⎦
⎥*100
Conduit vessel dilation is attenuated (smaller %FMD) in
individuals with CAD [26].
Twelve-segment carotid IMT and brachial FMD have
been standardized and validated in previous studies at
the Core Carotid Ultrasound Laboratory (Hamilton,
Ontario), with intraclass correlation > 90% and coeffi-
cient of variation < 5% for repeat examinations [13,30].
Statistical analysis
Continuous variables are expressed as mean (standard
deviation), while categorical variables are expressed as
count (percent) unless otherwise stated.
Figure 1
Flowchart of patients.
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shouldcorrelatewellwithtraditionalvascularriskfactorsfor
them to be considered good measures of extent, severity or
progression of atherosclerosis". This formed the basis for
assessment of construct validity. Multiple linear regression
models were used to examine the association between
baselinecarotidIMTorbrachialFMDandthewell-validated
traditional "Framingham" cardiovascular risk factors of age,
malegender,currentsmokingstatus,systolicbloodpressure
(SBP) and total:HDL cholesterol ratio using the cross-
sectional data. Goodness-of-fit was evaluated by plotting
the residuals from models to assess the normality assump-
tion. The distribution of residuals should approximate the
normaldistributionforgoodmodelfit.Wealsousedtheco-
efficientofdetermination(R
2) toquantifytheproportion of
variation in the dependent variable explained by the
independent variables included in the multiple regression
models [34].
Fixed effects models were used to study the relationship
between progression of carotid IMT or brachial FMD and
known cardiovascular risk factors using the progression
data. Fixed effects models are useful for longitudinal
data in which changes in time-varying covariates such as
age, total:HDL cholesterol and SBP may affect the
repeated outcome of interest [35]. There is no reason
to assume that these quantities are constant over time.
Further, the correlation between baseline and follow-up
response is incorporated into model specification by
assuming a plausible correlation structure. We assumed a
"continuous time" version of the auto-regressive (AR(1))
correlation structure (available only for mixed/fixed
effects models in SAS
© software), to adjust for irregula-
rities in follow-up times [36]. The reason is that many
scheduled follow-up visits were not feasible due to
circumstances beyond the control of investigators, thus
resulting in differential follow-up times for patients. A
time variable was created by designating the first visit for
each patient as (t1 = 1) and follow-up visits as
tt 21 =+ ⎛
⎝
⎜
⎞
⎠
⎟
⎧ Date of second visit - Date of first visit
365 ⎨ ⎨
⎩
⎫
⎬
⎭
The time component is closer to reality by making it a
continuous, rather than a discrete, variable. Model fit
was assessed using the "Null Model Likelihood Ratio
Test" [37]. The "Null Model Likelihood Ratio Test" is a
l i k e l i h o o dr a t i ot e s to fw h e t h e rt h em o d e lw i t haspecified
covariance structure fits better than a model where
repeated responses are assumed independent.A ni n d e -
pendent covariance structure is often implausible for
repeated measures data. A p-value < 0.05 for the
likelihood ratio test shows that the fitted model is better
than an independent covariance structure model [37].
Model adequacy was also evaluated using Akaike's
Information Criterion (AIC) to compare between "con-
tinuous time" and "fixed time" AR(1) structures. A
smaller AIC indicates better fit [37].
We evaluated the nature of the relationship between
baseline carotid IMT and brachial FMD using Pearson
correlation co-efficient.
Patients were classified as very low, low, medium/high
risk if individual Framingham risk scores were < 5%, 5–
9% and ≥ 10% respectively [38]. The medium and high
risk categories were combined due to limited numbers of
subjects in these categories. Framingham risk scores
quantify the 10-year risk of developing "hard" coronary
heart disease including myocardial infarction and
coronary death [38]. Framingham risk score is a strong
predictor of coronary heart disease [38]. One-way
analysis of variance (ANOVA) models were used to
cross-sectionally examine differences in brachial FMD or
carotid IMT by Framingham risk group classification.
We adjusted for current use of statin medication and
CD4 count in each regression model. All statistical tests
were conducted at 5% significance level. Graphs and
analysis results were obtained using SPSS Version 15.0
(SPSS Inc., Chicago, Illinois, USA) and SAS Version 9.1
(SAS Institute Inc., Cary, NC, USA).
The authors had full access to the data and take
responsibility for its integrity. All authors have read
and agree to the manuscript as written.
Results
Baseline and follow-up characteristics
Cross-sectional data
Therewere 257 patientsinthe baseline extentdatawith 232
(90.3%) males and 25(9.7%) females. Carotid IMT ranged
from 0.47 mm to 2.24 mm, with mean(SD) of 0.81(0.23)
mm. Brachial FMD ranged from -7.36% to 29.96%, with
mean(SD) of 4.95(4.50)%. We found a weak inverse
relationship between carotid IMT and brachial FMD at
baseline (r = -0.126; p = 0.043; see Figure 2). Other patient
characteristics are listed in Table 1.
Stratifying by Framingham risk group, dose-response
relationships were found between risk group classifica-
tion and carotid IMT or brachial FMD (Table 2). Carotid
IMT differed significantly between risk groups from
ANOVA analysis (p < 0.001). Brachial FMD did not
differ significantly across the risk groups from ANOVA
results (p = 0.227).
Of the 257 patients assessed at baseline, information on
anti-retroviral therapy was available for 253 individuals.
AIDS Research and Therapy 2009, 6:11 http://www.aidsrestherapy.com/content/6/1/11
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Abacavair, 106 (42%) were on Zidovudine, 61 (24%)
on Stavudine, 21 (8%) on Didanosine, 98 (39%) on
Efavirenz, 21 (8%) on Nelfinavir and 21 (8%) on
Nevirapine. However, we did not test the effects of HIV
medications on Carotid IMT/brachial FMD as that was
not part of our main goal, which was to validate these
measures against traditional risk factors.
Progression data
There were 168 patients in the progression dataset with
151(89.9%) males and 17(10.1%) females. Median
(interquartile range) follow-up time was 1.02 (0.43)
years. At baseline, carotid IMT varied from 0.47 mm to
1.57 mm with mean(SD) of 0.82(0.22) mm, while
brachial FMD varied from -6.81% to 29.96% with mean
(SD) of 5.10(4.58)%. At one-year follow-up, the
measures ranged from 0.50 mm to 1.57 mm with
mean(SD) of 0.84(0.23) mm and -13.61% to 25.52%
with mean(SD) of 4.40(4.96)% respectively. On average,
carotid IMT progressed at 0.02(standard error (SE) =
0.01) mm/year while brachial FMD decreased at 0.84
(SE = 0.79)%/year. Summary statistics for other variables
are listed in Table 3. Summary data for patients excluded
from the progression analyses are summarized in
Table 4. Patient distribution appears to be comparable
in both included and excluded data, except for viral load
and current statin use.
Examining the data cross-sectionally at baseline and
follow-up, there was a dose-response relationship between
carotid IMT and risk group classification (Table 5).
Carotid IMT differed significantly by risk group classifi-
cation at baseline and follow-up (p < 0.001 respectively
in each case). There was neither a dose-response relation-
ship nor significant difference in brachial FMD across
Figure 2
Carotid IMT versus brachial FMD at baseline.
Table 2: Baseline characteristics for extent data by Framingham
risk group
Risk group Number of
subjects
IMT
(mm)
FMD
(%)
Very low (< 5%) 88 0.68 (0.13) 5.58 (5.45)
Low (5 to 9%) 64 0.78 (0.16) 4.86 (3.59)
Medium/High (10% and above) 105 0.93 (0.27) 4.47 (4.08)
N B )E n t r i e sf o rI M Ta n dF M Da r er e p o r t e da sm e a n( s t a n d a r d
deviation); IMT increases significantly with increasing Framingham risk
(p < 0.001)
Table 1: Baseline characteristics for extent data (n = 257)
Variable Estimate
Male* 232 (90.3)
Age (years)
# 46.48 (7.86)
Carotid Artery Intima Media Thickness (IMT, mm)
# 0.81 (0.23)
Flow Mediated Vasodilation (FMD, %)
# 4.95 (4.50)
Total:HDL Cholesterol
# 5.28 (1.33)
Systolic Blood Pressure (mm Hg)
# 120.5 (15.6)
Current Smoking Status* 1 96 (37.5)
Current STATIN use* 1 18 (7.0)
CD4 Count
# 479.9 (270.6)
Log10 Viral Load
# 2.2 (1.2)
NB) 1 = current smoker/user; * = count(%); # = mean(standard
deviation)
Table 4: Baseline characteristics of excluded cases (n = 89)
Variable Baseline
Male* 81(91)
AGE (years)
# 45.16 (6.80)
IMT (mm)
# 0.79 (0.26)
FMD (%)
# 4.67 (4.36)
SBP (mm Hg)
# 120.8 (15.6)
Total: HDL Cholesterol
# 5.04 (1.18)
Current smoking status* 1 36 (40.9)
Current STATIN use* 1 9 (10.1)
CD4 Count
# 451.14 (275.51)
Log10 Viral Load
# 2.4 (1.3)
NB) 1 = current smoker/user; * = count(%); # = mean(standard
deviation)
Table 3: Baseline and follow-up characteristics for progression
data (n = 168)
Variable Baseline Follow-up
Male* 151 (89.9)
AGE (years)
# 47.19 (8.29) 48.25 (8.34)
IMT (mm)
# 0.82 (0.22) 0.84 (0.23)
FMD (%)
# 5.10 (4.58) 4.40 (4.96)
SBP (mm Hg)
# 120.4 (15.7) 121.1 (13.7)
Total: HDL Cholesterol
# 5.40 (1.39) 5.18 (1.17)
Current smoking status* 1 60 (35.7)
Current STATIN use* 1 9 (5.4)
CD4 Count
# 495.0 (267.6) 571.3 (883.2)
Log10 Viral Load
# 2.0 (1.1) 2.1 (1.2)
NB) 1 = current smoker/user; * = count(%); # = mean(standard
deviation)
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0.312 respectively).
Validity of baseline extent measures (cross-sectional data)
Goodness-of-fit tests were satisfied. The distribution of
residuals did not deviate systematically from the normal
distribution. Validity of measurement method was
assessed by how well each method correlated with
classical cardiovascular risk factors at baseline. From
multiple regression models: older patients (p < 0.001),
male patients (p = 0.034), current smokers (p < 0.001),
patients with higher SBP (p < 0.001), or higher total:
HDL cholesterol (p = 0.004) were statistically signifi-
cantly associated with higher carotid IMT (Table 6). The
cardiovascular risk factors explained approximately 45%
of the variation in carotid IMT (R
2 = 0.45). Neither
current statin use nor CD4 count were statistically
significantly associated with IMT (p = 0.904 and 0.929
respectively).
In contradistinction, none of these risk factors was
significantly associated with brachial FMD (Table 6). The
cardiovascular risk factors explained only 3% of the
variation in brachial FMD (R
2 = 0.031). Current use of
statins explained negligible amount of variation in both
IMT and FMD regression models. It should however be
noted that the percentage of patients on statin was very
small to make strong inferences regarding the effect of
the drug.
Responsiveness to change (progression data)
The "continuous time" AR(1) structure was assumed for
carotid IMT while the "fixed time" structure was assumed
for brachial FMD using results from the AICs. Both
models provided better fits than the independent
correlation structure model from the "Null Model
Likelihood Ratio" tests.
From fixed-effects models, positive change in carotid
IMT was statistically significantly associated with older
age (p < 0.001), male gender (p = 0.005), and current
smoking status (p = 0.011). Increase in SBP or total:HDL
cholesterol was not statistically significantly associated
with progression of carotid IMT (Table 7).
In comparison to non-statin users, patients on current
(baseline) statin medication had significantly better
FMD response after one-year follow-up (mean difference
= 3.11, 95% CI: 0.53 to 5.69). None of the traditional
cardiovascular risk factors was significantly associated
with progression of brachial FMD (Table 7).
Discussion
Non-invasive, validated and reproducible arterial ima-
gingtechniques such as brachial FMD and carotidIMTare
often used to measure the extent, severity or progression
of subclinical atherosclerosis in vascular health studies
[13,20]. Brachial FMD is a measure of endothelial
dysfunction [13,20] whereas carotid IMT measures
structural vascular integrity [13]. Studies have shown
that anti-atherogenic interventions such as statins, angio-
tensin-converting enzyme (ACE) inhibitors and other
blood-pressure lowering agents help to improve brachial
FMD [13,32,39,40], and retard carotid IMT progression
[12,13,30,31], thus highlighting the importance of both
measures in the atherosclerotic process.
Table 5: Baseline and follow-up characteristics for progression data by Framingham risk group
Risk group Number of subjects IMT 1 (Baseline) IMT 2 (Follow-up) FMD 1 (Baseline) FMD 2 (Follow-up)
Very low (< 5%) 54 0.70 (0.14) 0.72 (0.15) 5.67 (5.88) 4.35 (4.36)
Low (5 to 9%) 46 0.78 (0.17) 0.78 (0.17) 4.83 (3.54) 5.29 (5.13)
Medium/High (10% and above) 68 0.94 (0.24) 0.97 (0.25) 4.83 (4.02) 3.84 (5.27)
NB) Entries for IMT and FMD are reported as mean(standard deviation); Reported to two decimal places.
Table 6: Estimates from multiple regression models for baseline of Carotid IMT and Brachial FMD (%)
CAROTID IMT BRACHIAL FMD
PARAMETER Est.* 95% CI p-value Est.* 95% CI p-value
Age (years) 0.016 (0.014, 0.019) < 0.001 -0.021 (-0.093, 0.051) 0.569
Male 0.081 (0.006, 0.155) 0.034 -1.738 (-3.601, 0.124) 0.067
Current smoking status 0.096 (0.050, 0.143) < 0.001 0.294 (-0.874, 1.462) 0.620
SBP (mm Hg) 0.003 (0.002, 0.005) < 0.001 -0.021 (-0.058, 0.016) 0.262
Total:HDL Cholesterol 0.026 (0.008, 0.043) 0.004 0.001 (-0.435, 0.438) 0.995
Current STATIN use -0.006 (-0.096, 0.085) 0.904 1.578 (-0.683, 3.839) 0.171
CD4 Count -0.000004 (-0.00009, 0.00008) 0.929 -0.001 (-0.003, 0.001) 0.512
NB) *Est. – Estimate.
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progression of brachial FMD was significantly associated
with any of the examined classical vascular risk factors.
The cardiovascular risk factors explained only 3% of the
variation in brachial FMD. Use of statin medication led
to statistically significant improvement in brachial FMD,
thus replicating results from other studies [39]. Extent of
carotid IMT was significantly associated with age, male
gender, current smoking status, SBP and total:HDL
cholesterol, whereas progression of carotid IMT was
significantly associated with age, male gender and
current smoking status. The cardiovascular risk
factors explained approximately 45% of the variation
in carotid IMT.
Our results on carotid IMT are similar to results obtained
in other vascular studies in both non-HIV [13,15,41,42]
and HIV subject populations [1,43]. In a cross-sectional
study involving 119 indigenous Australians at risk of
cardiovascular disease, carotid IMT was significantly
associated with traditional cardiovascular risk factors,
while brachial FMD was associated with none of the
examined risk factors [28]. A case-control study by
Lekakis et al [3] found a significant association between
extent of IMT and blood pressure, cholesterol and
glucose levels, duration of HIV disease and use of
protease inhibitors. In contrast, brachial FMD was only
associated with triglyceride measurements [3]. Yan et al
[13] in a cross-sectional analysis of data from a large
cohort of middle-aged healthy men found significant
associations between carotid IMT increase and age, SBP,
body mass index, total and LDL cholesterol and fasting
plasma glucose. Among all risk factors examined,
increasing SBP was the only one associated with
impaired brachial FMD [13]. In a small study (total
sample size = 37) involving a relatively homogenous
sample of adult HIV patients on anti-retroviral therapy,
Stein et al [44] found an association between impaired
brachial FMD and VLDL (very low density), IDL
(intermediate density), HDL and total cholesterol levels
[44]. Brachial FMD has been shown to correlate with
vascular risk factors in non-HIV subjects [24,27] and use
of protease inhibitors in HIV subjects [44].
We also found a weak inverse relationship between carotid
IMT and brachial FMD with borderline significance (r =
-0.126, p = 0.043). A much larger study (sample size of
1,578) by Yan et al [11] found no significant correlation (r =
-0.006, p = 0.82) between IMT and FMD in healthy middle-
agedmenwithoutcardiovasculardisease[11].Iraceetal[45]
found a moderate linear association between FMD and IMT
in treatment naïve subjects at risk of CAD (r = -0.217,
p = 0.058). In a large study involving 2,109 healthy adults
aged 24 to 39 years in Finland, Juonala et al [46] found a
statistically significant inverse relationship (p < 0.001)
between IMT and FMD, thus adding to a series of conflicting
results on the "true" nature of therelationship between these
two important measures. Several relatively smaller studies
have found significant inverserelationshipbetween IMT and
FMD suggesting that these two measures assess the same
"aspects and stages of early atherosclerosis" [47-52]. The
results from smaller studies are suspect due to sample size
limitation. Findings from Yan et al [13] suggest that brachial
FMD and carotid IMT are likely "unique" and unrelated
surrogates that assess varying aspects and stages vascular
disease [13]. In contrast, Juonala et al [46] suggest a strong
inverserelationship between FMD and IMT, which would be
expected if both measures are assessing the same construct.
However,wenotethatwhileYan etal[13] employed anIMT
method that includes both far and near walls of all segments
in the right and left carotid arteries (similar to our study),
Juonala et al [46] employed a method that includes only the
far wall of the left carotid artery. Perhaps this may serve to
explain the contrasting results.
Various explanations have been proposed for conflicting
results regarding brachial FMD in the literature. These
include heterogeneity in patient populations being
studied, different measurement protocols or inadequate
sample sizes [11,13,14]. In our study, brachial FMD was
measured using an extensively validated and reliable
method [13,31-33]. Rundek et al [11] suggest a possibly
Table 7: Estimates from fixed effects models for progression of Carotid IMT and Brachial FMD (%)
CAROTID IMT BRACHIAL FMD
PARAMETER Est.* 95% CI p-value Est.* 95% CI p-value
Time (years) 0.001234 (-0.01556, 0.01803) 0.8847 0.7342 (-0.2578, 1.7261) 0.1457
Age (years) 0.01550 (0.01235, 0.01865) < .0001 0.02485 (-0.04543, 0.09513) 0.4857
Male 0.1225 (0.03721, 0.2078) 0.0051 -0.1125 (-2.0420, 1.8169) 0.9085
Current smoking status 0.07073 (0.01658, 0.1249) 0.0108 -1.1385 (-2.3578, 0.08092) 0.0671
SBP 0.000726 (-0.00028, 0.001730) 0.1544 -0.02425 (-0.06244, 0.01395) 0.2116
Total:HDL Cholesterol 0.01051 (-0.00392, 0.02494) 0.1520 -0.2449 (-0.6936, 0.2038) 0.2824
Current STATIN use 0.06222 (-0.05335, 0.1778) 0.2893 3.1025 (0.5174, 5.6876) 0.0190
CD4 Count 0.0000009 (-0.00002, 0.000020) 0.9265 0.000085 (-0.00075, 0.000924) 0.8411
NB) *Est. – Estimate.
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atherosclerosis, independent of traditional vascular risk
factors. Thus beyond traditional vascular factors,
endothelial dysfunction may independently provide
additional prognostic information on atherosclerosis
through other risk factors not currently assessed
[11,13,20]. Nevertheless, the validity of brachial FMD
as a measure of cardiovascular risk in HIV remains
largely unproven. There is need for large, long-term
observational studies (with standardized FMD proto-
cols) to critically evaluate the specific role of brachial
FMD in atherosclerosis relating to HIV patients. The
results presented in our paper were based on baseline
and one-year follow-up results.
From our study, IMT progressed at an annual rate of
0.02 mm/year. Hsue et al [1] estimated the annual
progression of IMT as 0.074 mm/year in an ancillary
cohort study involving 121 HIV-infected adults [1]. The
distinction between progression estimates from different
studies may result from demographic or clinical differ-
ences in the HIV populations studied. Further, more
precise progression estimates can be obtained from
studies with longer follow-up such as the ongoing
"Canadian HIV vascular study". The Canadian HIV
vascular study also aims to investigate the relationship
between atherosclerotic progression, anti-retroviral drug
regimen and immune reconstitution.
There were significant cross-sectional dose-response rela-
tionships between baseline (or follow-up) carotid IMT
and Framingham risk group classification. Framingham
risk classification was a strong predictor of extent of
carotid IMT, thus highlighting the prognostic value of
risk group classification.
The use of fixed effects models to analyze progression data is
one of the strengths of our study. Fixed effects models allow
for the inclusion of time-varying covariates such as age, SBP
and total:HDL cholesterol. Changes in these covariates are
likely to affect progression of either brachial FMD or carotid
IMT, thus including this information in model specification
is vital to obtaining a closer representation of reality.
Secondly, the use of the "continuous-time autoregressive
correlation structure" option in SAS software allowed for
patients to have differential follow-up times, which more
closely depicts circumstances surrounding our study. Also,
informationonthecorrelationbetweenbaselineandfollow-
up outcome measures was included as part of model
specification.
Conclusion
Carotid IMT is a useful surrogate marker of extent and
progression of cardiovascular risk in HIV patients
35 years of age and older, correlating better than FMD
with established cardiovascular risk factors. Extent of
carotid IMT correlates well with current risk stratification
of patients using Framingham risk scores. Use of carotid
IMT in ongoing and future observational studies and
randomized trials may help to better define the athero-
sclerotic risk associated with HIV infection and with
specific HIV treatments.
Comparison of results across studies is often quite
difficult due to differing measurement protocols
employed by different investigators. Standardization of
protocols for FMD and IMT will aid the comparison of
r e s u l t sa c r o s ss t u d i e s .
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